The estimated Net Worth of Mark S. Md Gelder is at least $11.7 Tausend dollars as of 7 February 2023. Dr Gelder owns over 5,833 units of Onconova Therapeutics Inc stock worth over $11,729 and over the last 11 years he sold ONTX stock worth over $0.
Dr has made over 3 trades of the Onconova Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 5,833 units of ONTX stock worth $5,833 on 7 February 2023.
The largest trade he's ever made was exercising 5,833 units of Onconova Therapeutics Inc stock on 7 February 2023 worth over $5,833. On average, Dr trades about 1,429 units every 55 days since 2014. As of 7 February 2023 he still owns at least 11,729 units of Onconova Therapeutics Inc stock.
You can see the complete history of Dr Gelder stock trades at the bottom of the page.
Dr. Mark Stephen Gelder is the Chief Medical Officer at Onconova Therapeutics Inc.
Dr Gelder is 64, he's been the Chief Medical Officer of Onconova Therapeutics Inc since . There are 7 older and 4 younger executives at Onconova Therapeutics Inc. The oldest executive at Onconova Therapeutics Inc is Henry Bienen, 77, who is the Director.
Mark's mailing address filed with the SEC is C/O ONCONOVA THERAPEUTICS, INC, 12 PENNS TRAIL, NEWTOWN, PA, 18940.
Over the last 12 years, insiders at Onconova Therapeutics Inc have traded over $1,631,795 worth of Onconova Therapeutics Inc stock and bought 27,892,613 units worth $51,994,589 . The most active insiders traders include Capital, Llc Armistice Capi..., Capital Management, Llc 683 und Capital Partners L P Tyndall. On average, Onconova Therapeutics Inc executives and independent directors trade stock every 40 days with the average trade being worth of $294,478. The most recent stock trade was executed by Mark Patrick Guerin on 13 March 2024, trading 8,666 units of ONTX stock currently worth $8,666.
onconova therapeutics, inc. (nasdaq: ontx) is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. using a proprietary chemistry platform, onconova has created an extensive library of targeted anti-cancer agents designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. onconova has three product candidates in clinical trials and six active pre-clinical programs. onconova seeks to develop products that improve the outcome for cancer patients by directly addressing the disease, its recurrence, and the burden of side-effects associated with current methods of treatment.
Onconova Therapeutics Inc executives and other stock owners filed with the SEC include: